Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr-Jun;42(2):159-163.
doi: 10.1016/j.htct.2019.04.006. Epub 2019 Aug 10.

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients

Priscilla Cury de Camargo Cury  1 , Fabiana Higashi  2 , Flávia Fernandes Silva Zacchi  3 , Renata Bacic Palhares  4 , Adriana Alvares Quero  5 , Ana Luiza Miranda Silva Dias  5 , Edvan de Queiroz Crusoé  6 , Vania Tietsche de Moraes Hungria  2
Affiliations

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients

Priscilla Cury de Camargo Cury et al. Hematol Transfus Cell Ther. 2020 Apr-Jun.

Abstract

Background: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients, prompting the rationale for using antiangiogenic drugs in the treatment of these patients.

Objective: To assess angiogenesis in patients with MM at diagnosis and following treatment with an antiangiogenic drug.

Patients and methods: Twenty-three patients with newly diagnosed MM were treated with thalidomide-based regimens. Bone marrow evaluation was made before and following treatment and included angiogenesis assessment, which was quantified through microvessel density (MVD) determination, by means of anti-CD34 immunohistochemical labeling, and classified either as high MVD or low MVD, according to the mean CD34 count: above or below the median of 12.6.

Results: The pre-therapy median MVD was 12 (7.5-18.3) versus 8.7 (5.35-18.5) post-therapy, p=0.2114.

Conclusions: Our study found no reduction in MVD before and following treatment and, accordingly, we could establish no relationship between MVD and response to therapy in the sample we studied.

Keywords: Multiple myeloma; Pathological angiogenesis; Thalidomide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of median MVD at diagnosis and after therapy in the 16 patients.
Figure 2
Figure 2
Comparison of median MVD values pre- and post-treatment in patients who achieved VGPR.
Figure 3
Figure 3
Comparison of median MVD values pre- and post-treatment in patients who achieved PR.
Figure 4
Figure 4
Overall survival from diagnosis.
Figure 5
Figure 5
Overall survival from diagnosis in the two groups categorized as low and high MVD.
Figure 6
Figure 6
Progression-free survival from induction in the two groups categorized as low and high MVD.
See this image and copyright information in PMC

References

    1. Rajkumar S.V., Dimopoulos M.A., Palumbo A., Blade J., Merlini G., Mateos M.V. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. - PubMed
    1. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Edlemon P. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–1571. - PubMed
    1. Rajkumar S.V., Hayman S.R., Lacy M.Q., Dispenzieri A., Geyer S.M., Kabat B. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050–4053. - PMC - PubMed
    1. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–2498. - PubMed
    1. Kumar S.K., Anderson K.C. Immune therapies in multiple myeloma. Clin Cancer Res. 2016;15(22):5453–5460. - PubMed